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Abstract
AIM
To investigate whether duodenal lesions induced by 
major venous occlusions can be attenuated by BPC 157 
regardless nitric oxide (NO) system involvement.
METHODS
Male Wistar rats underwent superior anterior pancrea-
ticoduodenal vein (SAPDV)-ligation and were treated 
with a bath at the ligated SAPDV site (BPC 157 10 μg, 
10 ng/kg per 1 mL bath/rat; L-NAME 5 mg/kg per 1 
mL bath/rat; L-arginine 100 mg/kg per 1 mL bath/rat, 
alone and/or together; or BPC 157 10 μg/kg instilled into 
the rat stomach, at 1 min ligation-time). We recorded 
the vessel presentation (filled/appearance or emptied/
disappearance) between the 5 arcade vessels arising 
from the SAPDV on the ventral duodenum side, the 
inferior anterior pancreaticoduodenal vein (IAPDV) and 
superior mesenteric vein (SMV) as bypassing vascular 
pathway to document the duodenal lesions presentation; 
increased NO- and oxidative stress [malondialdehyde 
(MDA)]-levels in duodenum.
RESULTS
Unlike the severe course in the SAPDV-ligated 
controls, after BPC 157 application, the rats exhibited 
strong attenuation of the mucosal lesions and serosal 
congestion, improved vessel presentation, increased 
interconnections, increased branching by more than 
60% from the initial value, the IAPDV and SMV were 
not congested. Interestingly, after 5 min and 30 min 
of L-NAME and L-arginine treatment alone, decreased 
mucosal and serosal duodenal lesions were observed; 
their effect was worsened at 24 h, and no effect on the 
collateral vessels and branching was seen. Together, 
L-NAME+L-arginine antagonized each other’s response, 
and thus, there was an NO-related effect. With BPC 
157, all SAPDV-ligated rats receiving L-NAME and/or 
L-arginine appeared similar to the rats treated with 
BPC 157 alone. Also, BPC 157 in SAPDV-ligated rats 
normalized levels of NO and MDA, two oxidative stress 
markers, in duodenal tissues.
CONCLUSION
BPC 157, rapidly bypassing occlusion, rescued the 
original duodenal flow through IAPDV to SMV flow, an 
effect related to the NO system and reduction of free 
radical formation.
Key words: Major venous occlusion; Duodenal lesions; 
BPC 157; L-NAME; Bypassing; L-arginine; Reduction of 
free radical formation; Rats
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Up to now, application of prototype cyto-
protective agent BPC 157 induced bypassing of 
occlusion, in rats underwent vessels occlusions, through 
rapid collaterals presentation, and lesions and whole 
consequent syndrome (ischemic colitis; deep vein 
thrombosis, Virchow triad) were attenuated. In rats 
underwent superior anterior pancreaticoduodenal vein-
ligation, medication was with BPC 157, L-NAME; L-arginine, 
saline given alone and/or together at 1 min ligation time. 
Unlike severe course in controls, BPC 157 rats commonly 
exhibited strong attenuation of mucosal lesion and serosal 
congestion, since BPC 157 rescued original duodenal flow 
through inferior anterior pancreaticoduodenal vein to 
superior mesenteric vein flow.
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R, Pajtak A, Amic E, Vidovic T, Rakic M, Milkovic Perisa M, 
Horvat Pavlov K, Kokot A, Tvrdeic A, Boban Blagaic A, Zovak 
M, Seiwerth S, Sikiric P. Bypassing major venous occlusion 
and duodenal lesions in rats, and therapy with the stable gastric 
pentadecapeptide BPC 157, L-NAME and L-arginine. World J 
Gastroenterol 2018; 24(47): 5366-5378
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INTRODUCTION
We focused on major venous occlusions and duodenal 
lesions in the rat and treatment with the stable gastric 
pentadecapeptide BPC 157, which is a prototype 
cytoprotective agent used in ulcerative colitis and 
multiple sclerosis trials (LD1 not achieved) and is known 
to counteract duodenal lesions[1-10]. Rat duodenal lesion 
research is mostly based on cysteamine and acetic acid 
models[11-14]; investigations are sparse on the impact of 
major venous obstruction and whether recruitment of 
blood vessels to bypass obstruction may occur quickly, 
and if so, whether it may be facilitated by a suitable 
therapy. On the other hand, in rats that underwent 
other vessel occlusions (i.e., left colic artery and vein, 
infrarenal inferior caval vein[15,16]), after application of 
stable gastric pentadecapeptide BPC 157, the bypassing 
occurs through a rapid collateral presentation, and 
the lesions and consequent syndrome were largely 
attenuated. Rapidly reestablished arcade vessel 
interconnections upon BPC 157 application mitigated 
the harm in two ligations of the left colic artery and vein 
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and consequently alleviated ischemic colitis as well[15]. 
In rats with infrarenal inferior caval vein occlusion, 
the therapeutic effect occurs through the immediate 
presentation of the left ovaric vein (LOV) and other 
veins, bypassing the obstruction, and counteracting 
all the symptoms of Virchow’s triad[16]. The normalized 
levels of two oxidative stress markers, nitric oxide (NO) 
and malondialdehyde (MDA), in tissues as well as the 
reduced L-NAME and L-arginine effects showed BPC 157 
effectiveness over the NO-system background[15,16].
These findings were related[15,16] to the cyto-
protective agents, to the effects originally noted in the 
stomach, which is the rapid endothelial protection. 
Using BPC 157 as a prototype cytoprotective agent[15,16], 
these mechanisms can prevent and resolve adjacent 
ischemic mucosal lesions[17-21] providing activation 
of the collateral circulation[15,16]. This activation is 
specific and can circumvent obstructions[15,16]. That 
factor had not been considered in vascular studies 
of ischemic colitis or deep vein thrombosis[22-25]. As a 
result exerted within the immediate post-injury time 
in vascular studies of ischemic colitis or deep vein 
thrombosis[15,16], it reestablishes the continuity of blood 
flow, in particular[15,16]. Also, this effect was shown to be 
a long-lasting effect[15,16]. It was also applicable in the 
later period, even after additional colon or major vein 
obstruction had occurred[15,16]. 
This will also resolve mucosal lesions that would 
appear with disturbed duodenal circulation, if the 
cytoprotection/endothelium protection is essential[15,16] 
to quickly restore blood supply to the ischemic area, and 
if the application of BPC 157 may offer a fundamental 
treatment with the rapid and successful recruitment of 
blood vessels during harmful events. In support, various 
harmful conditions, all overwhelmed, such as vascular 
obstruction, short-lasting blood deprivation, reperfusion, 
long-lasting blood deprivation and additional bowel 
obstruction, verify that BCP 157 can rapidly activate 
collaterals as we suggested[15,16].
We treated occluded superior anterior pancrea-
ticoduodenal veins (SPDAVs) and duodenal lesions 
(that would otherwise rapidly appear and sustainably 
progress) with the stable gastric pentadecapeptide 
BPC 157, L-NAME and L-arginine. Namely, interaction 
between BPC 157 and NO-system goes in different 
systems and species. This was also demonstrated using 
both L-NAME and L-arginine as individual agents or in 
combination[1-5] in cytoprotection studies. Furthermore, 
venous obstruction may be more damaging to the 
intestine than corresponding artery occlusions and 
rapidly induces mucosal lesions (i.e., within 5 min in the 
case of the superior mesenteric vein)[26]. Thus, bypassing 
one or more of the vascular obstructions and thereby 
achieving a therapeutic effect[15,16] appears, if BPC 157 
rapidly activates collaterals due to its particular direct and 
rapid effect on vessel presentation. The main focus of the 
intervention was parallel with the findings in the colon 
and venous tissues[15,16]. Levels of oxidative stress MDA 
and NO were also assessed in duodenal tissue, and the 
results showed NO- and MDA- duodenal tissue levels and 
relative to the ligation course or therapeutic effects.
MATERIALS AND METHODS 
Animals
We used male Albino Wistar rats, 200 g b.w., randomly 
assigned to groups with at least 7 rats per group. Local 
ethics committee approved all of the experiments. 
Rats had access to food and water ad libitum before 
the procedure and until the end of the experiment. 
The surgical procedure was performed as well as the 
assessments were performed by a blinded observer.
Drugs
We used the pentadecapeptide Gly-Glu-Pro-Pro-Pro-
Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, M.W. 1419, 
named BPC 157 (Diagen, Ljubljana, Slovenia), freely 
soluble in water at pH 7.0 and in saline, prepared 
as previously described[1-10]. L-NAME (Sigma, United 
States) and L-arginine (Sigma, United States) were 
used as previously described[1-10].
Experimental procedure and assessment
Surgery: The surgery was conducted in deeply 
anesthetized rats. The SAPDV was occluded by ligation 
(Premilene 7/0, Braun) of 5 arcade vessels at the 
duodenal serosa within the SAPDV branches. The 
30-mm blood-flow affecting a duodenum segment was 
marked (Figure 1).
Medication: We used two regimens of BPC 157 
application: 10 μg, 10 ng/kg per 1 mL bath/rat or 10 
μg/kg instilled into the rat stomach, at 1 min ligation-
time. To investigate the effect of NO-agents [L-NAME 
(NO-system-blockade), L-arginine (NO-system 
over-stimulation); L-NAME+L-arginine (NO-system 
immobilization)] we used L-NAME 5 mg/kg per 1 mL 
bath/rat; L-arginine 100 mg/kg per 1 mL bath/rat, alone 
and/or together. Controls received a saline bath of equal 
volume at 1 min of ligation time or an equal volume of 
saline instilled into the stomach of the SAPDV-ligated 
rats.
Assessment: Considering the point immediately 
before therapy (as 100%) [see the assessment 
shown in Figure 1 (SAPDV rats)], we scored the vessel 
presentation {recorded filled/appearance or emptied/
disappearance [camera attached to a USB microscope 
(Veho discovery VMS-004 deluxe)]} between the 5 
arcade vessels arising from the SAPDV on the ventral 
duodenum side (as described before[15]), the IAPDV, 
SMV as bypassing vascular pathway. Scoring 0-3 was 
as follows: 0, presentation similar to healthy rats; 
1, mild congestion; 2, moderate congestion; and 3, 
severe congestion, after 5 min; then, at 30 min, at 24 
h. Likewise, upon the duodenum opening and after 
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h ligation time, we determined the NO levels (μmol/mg 
protein) in the duodenum tissue samples using the 
Griess reaction (Griess Reagent System, Promega, 
United States). Briefly, we added sulfanilamide to the 
homogenized tissue; we incubated the mixture, and 
added N-1-naphthylethylenediamine dihydrochloride. 
We measured absorbance at 540 nm using a sodium 
nitrite solution as a standard. We determined protein 
concentrations using a commercial kit (BioRad Protein 
DR Assay Reagent Kit, United States).
Statistical analysis
We used parametric one-way ANOVA with a post hoc 
Newman-Keuls test, nonparametric Kruskal-Wallis 
and subsequent Mann-Whitney U-test to compare 
the groups. We considered P < 0.05 to be statistically 
relevant.
RESULTS 
The regular perilous course in rats with SAPDV 
occlusion
Failure progressed in control SAPDV-ligated rats 
(5-30 min - 24 h). Lesions were more than 30 mm in 
diameter and included hemorrhagic mucosal lesions, 
serosal congestion (Figures 2-4) with deteriorating 
vessels, losing collaterals, and branching was present 
in 30% or less of the initial value at the end of the 
experiment (Figure 5). IAPDV and SMV were both 
congested (Figures 2 and 6). 
Microscopically (Figure 7), the lesions progressed 
from mild villous edema with mild lymphocytic infiltrate 
(5 min ligation time) toward denuded villous tops 
with marked villous edema and submucosal capillary 
congestion (30 min ligation time) to the substantial 
subepithelial space with abundant lifting of epithelial 
layer from lamina propira extending down sides of villi, 
villous edema with capillary congestion, submucosal 
congestion and lymphocytic infiltrate (24 h ligation 
time) (Figure 7). 
Oxidative stress and NO determination in duodenum 
tissue
The negative chain of events was first characterized by 
decreased NO levels and increased MDA levels in the 
duodenum tissue, followed by excessive NO release and 
increased MDA levels in the duodenum tissue (Figure 8).
The regular course in rats with SAPDV occlusion 
counteracted with BPC 157 therapy
In contrast, after BPC 157 therapy (applied directly to 
the duodenum as a bath, or instilled into the stomach), 
only a few treated rats exhibited more than 10 mm-
diameter mucosal lesions and serosal congestion 
(Figures 2-4). Frequently, vessel presentation was 
markedly improved with increased interconnections, 
and branching increased more than 60% from the 
initial value (Figure 5). IAPDV and SMV were both non-
sacrifice, we assessed the congested hemorrhagic 
areas as the sum of the largest lesion diameters[21,27-29]. 
As described previously[1-10,15,30], we processed the 
representative tissue sections for further histological 
analysis. 
Oxidative stress
As described before[15,16,31,32], at the end of the 
experiment and at 5 min, 30 min and 24 h of ligation 
time in SAPDV-ligated rats, we assessed the oxidative 
stress in the collected tissue samples by quantifying 
thiobarbituric acid-reactive species (TBARS) as MDA 
equivalents (results expressed in nmol per mg of 
protein). Briefly, we homogenized the tissue samples 
[in PBS (pH 7.4) containing 0.1 mmol/L butylated 
hydroxytoluene (BHT) (TissueRuptor, Qiagen, United 
States)] and sonicated [for 30 s in an ice bath (Ultrasonic 
bath, Branson, United States)], added trichloroacetic 
acid (TCA, 10%) to the homogenate, centrifuged the 
mixture (at 3000 rpm for 5 min), and collected the 
supernatant. Then, we added 1% TBA, boiled the 
samples (95 ℃, 60 min), and kept the tubes on ice for 
10 min. Following centrifugation (14000 rpm, 10 min), 
we determined the absorbance of the mixture at the 
wavelength of 532 nm. We assessed the concentration 
of MDA from a standard calibration curve plotted 
using 1,1,3,3’-tetraethoxypropane (TEP). We express 
the extent of lipid peroxidation as MDA using a molar 
extinction coefficient for MDA of 1.56 × 105 mol/L 
per cm and determined protein concentration using a 
commercial kit. 
NO determination in duodenum tissue
In SAPDV-ligated rats, as described before[15,16,31,32], at 
the end of the experiment and at 5 min, 30 min and 24 
Duodenum
Superior mesenteric vein
Inferior mesenteric vein
Superior anterior 
pancreaticoduodenal 
vein
Inferior anterior 
pancreaticoduodenal 
vein
Figure 1  Model illustration of major venous obstruction and duodenal 
lesions in rat. The major venous obstruction and duodenal lesions in rat, and 
therapy solution with the stable gastric pentadecapeptide BPC 157, model 
illustration. Superior anterior pancreaticoduodenal vein (SAPDV) was occluded 
by ligation (Premilene 7/0, Braun), 5 arcade vessels at duodenal serosa within 
the SAPDV tributaries, the 30-mm blood-flow disturbed duodenum segment 
was the marked area; inferior anterior pancreaticoduodenal vein and superior 
mesenteric vein as bypassing loop.  
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congested (Figures 2 and 6). Thereby, the treatment 
rescued the original duodenal flow through IAPDV to 
SMV flow, and the duodenal lesions largely diminished.
Microscopically, BPC 157 rats exhibited intestinal 
preservation with only mild villous edema and mild 
lymphocytic infiltrates. The elevation of the epithelium 
from the lamina propria was found only on the apical 
portion of the villi (after 24 h of ligation) (Figure 7).  
Oxidative stress and NO determination in the 
duodenum tissue with BPC 157 revealed an increase 
in the duodenal NO values up to the normal values, 
but normal MDA-values compared to the excessively 
increased values seen in the controls (Figure 8). 
L-NAME and L-arginine, given alone or together; BPC 
157 treatment
L-NAME and L-arginine treatment alone decreased 
mucosal and serosal duodenal lesions at 5 min and 30 
min. Their effects were less at 24 h, but they did not 
further influence the loss of the collateral vessels and 
branching. Together, L-NAME+L-arginine antagonized 
each other’s response at any treatment point, and thus, 
NO-related effects were seen. When treated with BPC 
157, all SAPDV-ligated rats receiving L-NAME and/or 
L-arginine responded similarly to the rats treated with 
BPC 157 alone (Figures 2, 5 and 6).
Thus, it seems that BPC 157 rescues SAPDV failure 
and duodenum lesions, and its effect is related to the 
NO system.
DISCUSSION 
We attempted to alleviate major venous obstruction 
and duodenal lesions in rats with stable gastric 
Inferior anterior pancreaticoduodenal vein and superior 
mesenteric vein congestion (score 0-3), min/med/max, after 
superior anterior pancreaticoduodenal vein (SAPDV) occlusion
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3
2
1
0
CON     Bμg     Bng
i.g.        i.g.       i.g.
a a a a a a
3
2
1
0
CON    Bμg     Bng       N         A       NA        BN      BA      BNA
a a a a a a a a a a a a a a a
50
40
30
20
10
0
CON    Bμg     Bng
i.g.        i.g.       i.g.
a
a
a
a
a
a
Sum of the longest lesion diameters, mm, means ± SD
50
40
30
20
10
0
CON    Bμg     Bng       N         A       NA       BN      BA     BNA
a
a
a
a
a
a
aa
a a
a
a
a
a a
a
a
a
a
a
a
SAPDV ligation-time
5 min
30 min
24 h
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Inferior anterior pancreaticoduodenal vein and superior 
mesenteric vein congestion (score 0-3), min/med/max, after 
superior anterior pancreaticoduodenal vein (SAPDV) occlusion
SAPDV ligation-time
5 min
30 min
24 h
SAPDV ligation-time
5 min
30 min
24 h
Figure 2  Duodenal lesions as a sum of the longest lesions diameters (left); Inferior anterior pancreaticoduodenal vein and superior mesenteric vein 
congestion, scored 0-3 (right). The gross appearance of the tissue was recorded using a USB microscope camera. At 1 min post-injury, medication [BPC 157, 10 
μg/kg (Bμg), 10 ng/kg (Bng), L-NAME, 5 mg/kg (N), L-arginine, 100 mg/kg (A) alone and /or together (NA, BN, BA, BNA) 1 mL bath/rat] or an equal volume of a saline 
was applied to the duodenum of the superior anterior pancreaticoduodenal vein (SAPDV)-ligated rats (upper); alternatively, at 1 min post-injury, medication was Bμg 
i.g., Bng i.g., 1 mL inistillation into the stomach or an equal volume of a saline instilled into the stomach of the SAPDV-ligated rats (CON i.g.) (lower). The rats were 
sacrificed 5 min, 30 min or 24 h later. aP < 0.05 vs saline. Bng: BPC 157, 10 ng/kg; Bμg: BPC 157, 10 μg/kg; N: L-NAME, 5 mg/kg; A: L-arginine, 100 mg/kg; NA: 
L-NAME+L-arginine; BN: BPC 157+L-NAME; BA: BPC 157+L-arginine; BNA: BPC 157+L-NAME+L-arginine; SAPDV: Superior anterior pancreaticoduodenal vein.
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pentadecapeptide BPC 157 treatment and to investigate 
its relation to the NO system[1-10]. In duodenal lesion 
development, the occlusion of the SAPDV appears as 
the key failure (before other vessel occlusions: i.e., 
left colic artery and vein ligation, and inferior caval 
vein ligation)[15,16] that could never be spontaneously 
alleviated, even though well-placed vessels or 
additional therapy with NO agents [NOS-over-activation 
(L-arginine) and/or NOS-blockade (L-NAME)]. On the 
other hand, BPC 157 therapy resulted in promptly 
alleviated vascular presentation and then alleviated a 
perilous course of duodenal lesions in rats with SAPDV 
occlusions. We documented again “running” toward 
the bypassing vessel occlusion(s)[15,16] and that BPC 
157 after SAPDV occlusion quickly restores the blood 
supply to the ischemically injured area. BPC 157 rapidly 
activates collaterals much like a fundamental treatment 
that counteracted the injurious course (ischemic 
colitis[15]; the syndrome resulting from inferior caval vein 
infrarenal-ligation[16]) and this effect involves the NO 
system and reduction of free radical formation[15,16].  
The SAPDV-ligated rats treated with BPC 157 
exhibited a complete reduction of the SAPDV-occlusion 
syndrome: improved vessel presentation, increased 
interconnections, duodenal arcade branching increased 
up to 60% from the initial value, and uncongested 
IAPDV and SMV. Thereby, BCP 157 treatment rescued 
the original duodenal flow through IAPDV to SMV flow 
and largely mitigated the duodenal lesions (Figures 
2-6). The results provide consistent evidence for the 
beneficial effects of a rapid and sustained BPC 157 μg 
and ng regimen.
In addition, we clarified the distinction between 
BPC 157 and NO-agent activity. We assumed that a 
prolonged occlusion would result in a more severe 
lesion and that a persisting and powerful defensive 
process would oppose these injuries and assure long-
lasting protection. Thus, BPC 157 therapy, along with 
the findings mentioned before[15,16], exhibited a special 
“bypassing” effect (through arcade vessels and/or minor 
and major vessels[15,16]) making vascular occlusion 
harmless and reorganizing the blood flow to counteract 
the duodenal lesions in rats with SAPDV-ligation. 
Similar to occlusion of the other vessels[15,16], this study 
indicates the early positive outcome (“bypassing” 
effect) of BPC 157 that may be crucial for its persisting 
beneficial effect, even with continuous occlusions. The 
effect of BPC 157 in rats with SAPDV-ligation and rats 
with left colic artery and vein ligations may indicate 
that the action of BPC 157 overlaps in the duodenum 
and colon[15,16]. BPC 157 plays an important role in 
with respect to the “bypassing” effect that maintains 
duodenum and colon mucosal integrity[15,16] and 
interacts with the NO system (L-NAME and L-arginine 
exhibited parallel effects (lesion worsening), which 
mitigated each other) in SAPDV, left colic artery and 
vein circulation, and duodenal and colon lesions[15,16]. 
Together, the “bypassing” effect combined with 
duodenum (and colon) mucosal integrity as the revealed 
phenomenon could be quite complex[15,16] as it was 
        Superior anterior pancreaticoduodenal vein 
occlusion
Ligation time
1 min
Therapy 
application
Immediately after 
therapy application
L
T
TB
TS
TB
TS
T
A
B
Figure 3  Characteristic appearance of the duodenum in superior anterior 
pancreaticoduodenal vein-ligated rats. A: The characteristic appearance 
of the duodenum in superior anterior pancreaticoduodenal vein (SAPDV)-
ligated rats after ligation (before therapy), and then with therapy: during and 
immediately after medication bath [saline (upper); BPC 157 (lower) application; 
duodenum opening before sacrifice at 5 min ligation-time; USB microscope 
camera]. Therapy with saline bath. Congested duodenal serosa and duodenal 
arcades with few vessels branching before, during and after medication saline 
bath. The congested haemorrhagic area was observed upon duodenal opening 
after saline bath treatment in rats that underwent obstruction of the SAPDV 
for 5 min. Therapy with BPC 157 bath. Immediately with BPC 157 medication 
applied as a bath apparently not congested serosa and vessels with increased 
branching replaced congested duodenal serosa and duodenal arcades with 
few vessel branching. Area without apparent congestion and haemorrhage 
was observed upon duodenal opening after BPC 157 bath treatment in rats 
that underwent obstruction of the SAPDV for 5 min; B: High magnification of 
presentation with ligation, and presentation of the moment immediately with 
therapy application, as saline bath as medication, or BPC 157 bath medication. 
L: Ligation; T: Therapy; TS: Therapy with saline bath; TB: Therapy with BPC 157 
bath; C: Congested haemorrhagic area; B: Area without apparent congestion 
and haemorrhage.
B
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seen with respect to the L-NAME (NOS blockade) and 
L-arginine (NOS over-activity) treatments, which given 
alone and/or together (NO-system immobilized) never 
exhibited the “bypassing” effect and did not provide any 
mucosal protection[15,16]. However, when given together 
with BPC 157 (L-NAME+BC 157; L-arginine+BPC 157; 
L-NAME+L-arginine+BPC 157), with either SAPDV-
ligation or left colic artery and vein ligation, the BPC 157 
beneficial effect was observed, compensating either the 
L-NAME and L-arginine effects, while mucosal protection 
was seen at a higher level.
It is possible that the environment created by 
vessel(s) occlusion is responsible for the “bypassing” 
effect (SAPDV-duodenal arcade vessel interconnections-
IAPDV-SMV required for adequate compensation and 
duodenal mucosal protection consistently obtained 
by BPC 157 administration) and remains outside the 
regular L-NAME or L-arginine influence on blood vessels 
but inside BPC 157 influence on NO-agent effects. 
L-NAME and L-arginine were given in doses necessary 
to instantly induce hypertension or hypotension[33], 
while both effects were counteracted by BPC 157 
administration[33]. Providing a complex beneficial effect, 
BPC 157 did not affect normal blood pressure[33]; in 
addition to counteracting L-NAME induced hypertension 
and L-arginine induced hypotension[33], when BPC 157 
counteracted arterial[34] or venous hypertension[16] or 
systemic hypotension[16], it also counteracted other 
disturbances, which may be related to blood pressure 
disturbances (i.e., potassium-overload induced 
arrhythmias[34]; Virchow’s triad[16]; chronic heart failure 
induced by doxorubicin in hypotensive rats and mice[35]; 
venous hypertension in systemically hypotensive rats 
with inferior caval vein occlusion[16]). Therefore, in 
SAPDV-ligated rats, venous occlusion alone causes 
severe congestion and increased intravascular 
pressure[26]; the vessels hampered with occlusions 
would fail to respond to either NO agent. On the 
other hand, this complete failure is not present in left 
colic artery and vein ligated rats[15] (arterial occlusion 
results only in reduced inflow perfusion with normal 
outflow[26], arteriovenous occlusion balances inflow and 
outflow alteration). Thus, the arteriovenous occlusion, 
intravascular pressure and tone equilibrium[26] (left colic 
artery and vein ligated rats[15]) still permits NO-agents 
activity, unlike the venous occlusion, severe congestion 
and increased intravascular pressure[26] (SAPDV-ligated 
rats). Syndrome in left colic artery and vein ligated 
rats[15] [the decrease (L-NAME) or increase (L-arginine) 
in vessels], but without the vessel interconnection and 
bypassing effect, worsening the mucosal lesions (even 
after the initial short-lasting protective effect) accords 
with the more severe syndrome in SAPDV-ligated rats 
(vessels unresponsive to NO-agents) (Figure 5). 
The common failure to heal SAPDV or left colic artery 
and vein occlusions[15], parallelism much like in other 
models[15,35,36], substantiates particular aspect of a NO 
system dual (L-NAME vs L-arginine) role (vs combination) 
(for review, see[1-5]). Parallel L-NAME/L-arginine activity, 
which was noted as parallel outcomes, as a specific 
point (much like before[15,35,36], L-NAME and L-arginine 
regularly attenuated or antagonized each other’s 
responses, presenting values comparable to the control), 
also appeared with two pharmacologically distinct 
B
C
B
C
Figure 4  Characteristic appearance of the duodenum in superior anterior pancreaticoduodenal vein-ligated rats at 30 min (left) or 24 h (right) ligation-
time. After medication bath [saline (upper) (C); BPC 157 (lower) (B) application]; duodenum opening before sacrifice at 30 min (left) or 24 h (right) ligation-time; 
USB microscope camera. Control: 30 min. Congested duodenal serosa and duodenal arcades with few vessel branching. Congested haemorrhagic upon duodenal 
opening. 24 h. Severely congested duodenal serosa and duodenal arcades with few vessel branching. Severely congested haemorrhagic upon duodenal opening. 
BPC 157 therapy: 30 min. Not congested serosa and vessels with increased branching. Area without apparent congestion and haemorrhage was observed upon 
duodenal opening: 24 h. Not congested serosa and vessels with increased branching. Area without apparent congestion and haemorrhage was observed upon 
duodenal opening. C: Control; B: BPC 157.
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mechanisms with opposing effects on the same signaling 
pathway (for review, see[1-5]). In SAPDV-ligated rats, this 
parallelism is constant with also distinctive effects, lesion 
attenuation (early intervals) vs lesion worsening (late 
interval), unless BPC 157 had been administered and 
the beneficial effect always attenuated the lesion[15,35,36]. 
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Figure 5  Percent of vessels present between 5 arcade vessels on the ventral side of the duodenum in different time points. Percent of vessels present 
between 5 arcade vessels on the ventral side of the duodenum 1 min following ligation before therapy (as 100%) (A); mean ± SD. The gross appearance of the tissue 
was recorded using a USB microscope camera. The following time points were assessed: A: After ligation and before therapy (1 min); B: 5 min after the application of 
medication; C: 30 min after the application of medication; D: 24 h after the application of medication. At 1 min post-injury, medication [BPC 157, 10 μg/kg (BPC 157 
μg), 10 ng/kg (BPC 157 ng), L-NAME, 5 mg/kg (L-NAME), L-arginine, 100 mg/kg (L-arginine) alone and/or together (L-NAME+L-arginine, BPC 157+L-NAME,BPC 
157+L-arginine, BPC 157+L-NAME+L-arginine) 1 mL bath/rat] or an equal volume of a saline was applied to the duodenum of the SAPDV-ligated rats (upper); 
alternatively, at 1 min post-injury, medication was BPC 157 μg, BPC 157 ng, 1 mL inistillation into the stomach or an equal volume of a saline (saline) instilled into the 
stomach of the superior anterior pancreaticoduodenal vein-ligated rats (lower). The rats were sacrificed 5 min, 30 min or 24 h later. For clarity, the SD is not shown on 
the graph; the SD was never higher than 10% of the mean. aP < 0.05 vs saline. BPC 157 μg: BPC 157, 10 μg/kg; BPC 157 ng: BPC 157, 10 ng/kg; L-NAME: L-NAME, 
5 mg/kg; L-arginine: L-arginine, 100 mg/kg.
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Likewise, if the NO system immobilized (mutual actions 
of the combined L-NAME and L-arginine), it still produces 
the severe pathology in the L-NAME+L-arginine animals. 
If this remained severe pathology is further attenuated, 
it means that the other system(s) (likely cholinergic 
and BPC 157) functioned along with. In this view, the 
particular role of BPC 157 reestablished effectiveness 
(L-NAME+L-arginine → L-NAME+L-arginine+BPC 157). It 
means that BPC 157 is effective (L-NAME+L-arginine+BPC 
157; L-arginine+BPC 157; L-NAME+ BPC 157) with all 
of the NO-system presentations [inactivated (L-NAME 
+ L-arginine); overstimulated (L-arginine); or blocked 
(L-NAME)][15,35,36]. Thus, the three distinct NO-endpoints 
(NO-immobilization; -over-activity; -blockade) should be 
overwhelmed to achieve vessel presentation seen in rats 
that underwent BPC 157 treatment[15,35,36]. BPC 157 may 
consolidate the NO system to produce more effective 
healing (i.e., the stimulatory and inhibitory effects of 
the NO system promoted the interconnection of arcade 
vessels to bypass major obstructions) (a result not 
observed with L-NAME or L-arginine treatment)[15].
This special BPC 157 role seems to be supported 
by the NO and MDA values seen in the duodenal 
tissues. The beneficial effects promptly counteract 
the full negative syndrome. Otherwise, after SAPDV-
ligation, sudden decrease of blood supply appears. NO-
levels decrease in the duodenum tissue. Heavy loss of 
endothelial cells occurs immediately from the vascular 
wall[37]. A lower eNOS production ability[37], oxidative 
stress appears as a result of the lysis of endothelial 
cells[38,39]; and excessive NO release generated by 
the inducible isozyme damaging the vascular wall 
and other tissues cells, especially in combination with 
reactive oxygen intermediates, and failing endothelial 
production[32,40,41]. The positive chain of events includes 
a BPC 157 treatment restored endothelial integrity 
and reversed most of the oxidative damage[15,16,31,32] 
while interacting with the NO system[1-5]. The positive 
endothelium syndrome (i.e., increased duodenal NO-
values, but normal MDA-values, indicative of adequate 
eNOS system function[1-5]) appears with general 
significance, and thereby, restored endothelial integrity 
and reversed most of the oxidative damage. With BPC 
157, this recovery appears even during reperfusion 
(occurring while vessel occlusion is still present) much 
like during exaggerated reperfusion (occurring when 
vessel occlusion is removed)[15].
There is evidence that BPC 157 also affects several 
other molecular pathways[16,42-47], and thereby, the rapid 
recruitment of existing blood vessels following ongoing 
harmful events instead otherwise poor response to 
increased demands. Combined, these findings may 
substantiate the effects of which were seen at the 
later time point. In addition, this may accentuate the 
original cytoprotection understanding (endothelium 
maintenance → epithelium maintenance)[17-21] to the 
complexity of reestablishing original flow by bypassing 
occlusion[15,16]. And thereby, we documented recovery of 
SAPDV-occlusion by AIPDV → SMV, or ICV-occlusion by 
LOV and other veins[16], or even two obstructions, the 
proximal and distal ligations in the left colic artery and 
vein through arcades within the ligations in rats with 
colitis[15]. Furthermore, its subsequent strong angiogenic 
effect and its healing effects[9,43-49]may be consequence of 
the specific activation of the collateral circulation that can 
circumvent obstructions and reestablish the continuity 
of blood flow[15,16]. And thereby, its angiogenic effect and 
its healing effects[9,43-49] may overcome those of standard 
anti-ulcer agents[48]. Also, these effects are likely to 
be further extended. BPC 157 accelerates the blood 
flow recovery and vessel number in rats with hindlimb 
ischemia[43]. BPC 157 upregulates VEGFR2 expression in 
rats with hindlimb ischemia and endothelial cell cultures 
and promotes VEGFR2 internalization in association with 
VEGFR2-Akt-eNOS activation[43]. As mentioned, shared 
limitation of activity[17-21,50], only prophylactic effectiveness 
of standard cytoprotective agents, is avoided. With 
both prophylactic and therapeutic abilities[1-10], native 
and stable in human gastric juice BPC 157 as a novel 
mediator of Robert’s cytoprotection[1-10] maintains 
gastrointestinal mucosal integrity[1-10]. In addition, the 
comparative effectiveness of BPC 157 when instilled into 
BC
Figure 6  Characteristic appearance of inferior anterior pancreaticoduodenal and superior mesenteric vein presentation in superior anterior 
pancreaticoduodenal vein-ligated rats at 24 h ligation time. Control, left (C). Congested inferior anterior pancreaticoduodenal and superior mesenteric vein 
presentation along with duodenal serosa and arcade vessels. during and immediately after medication bath [saline (C); BPC 157, right (B)]. Presentation close to 
normal, unlike congested inferior anterior pancreaticoduodenal and superior mesenteric vein presentation along with duodenal serosa and arcade vessels in controls. C: 
Control; B: BPC 157.
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the stomach supports this contention of a prototype of a 
more effective class of cytoprotective agents.
In conclusion, this study provides evidence for a 
“bypassing” effect combined with mucosal integrity (i.e., 
duodenum and colon) or major vessel obstruction made 
harmless[15,16] as observed after BPC 157 treatment, 
which can be regarded as an implementation of the 
original cytoprotection concept in vascular occlusion 
therapy. 
ARTICLE HIGHLIGHTS
Research background
The research background was our recent claim that treatment with the prototype 
cytoprotective agent, stable gastric pentadecapeptide BPC 157, induced 
bypassing of occlusions in rats that underwent vessel occlusions through the 
rapid presentation of collaterals. In this study, we focused on the resolving of 
the duodenal lesions induced by major venous occlusions. These lesions can 
be counteracted by BPC 157 regardless of the involvement of the nitric oxide 
(NO) system while recruitment of blood vessels to bypass obstruction may 
occur quickly.
Research motivation
Research motivation was to resolve the major venous occlusions and duodenal 
lesions in the rat with the use of the stable gastric pentadecapeptide BPC 157 
and/or NO-agents, L-NAME (NOS-blocker) and L-arginine (NOS-substrate). 
BPC 157 is a prototype cytoprotective agent used in ulcerative colitis and 
multiple sclerosis trials (LD1 not achieved) and is known to counteract duodenal 
lesions. Rat duodenal lesion research is mostly based on cysteamine and 
acetic acid models. Investigations are sparse on the impact of major venous 
obstruction and whether recruitment of blood vessels to bypass obstruction may 
occur quickly, and if so, whether it may be facilitated by a suitable therapy. 
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Figure 7  Microscopical presentation of duodenal lesions. Microscopically (Hex10), in controls the lesions progressed from mild villous edema with mild 
lymphocytic infiltrate (5 min ligation time) (A) toward denuded villous tops with marked villous edema and submucosal capillary congestion (30 min ligation time) (B) 
to the substantial subepithelial space with abundant lifting of epithelial layer from lamina propria extending down sides of villi, villous edema with capillary congestion, 
submucosal congestion and lymphocytic infiltrate (24 h ligation time) (C). BPC 157 rats (D, E, F) exhibited always intestinal preservation with only mild villous edema 
and mild lymphocytic infiltrate. Elevation of epithelium from lamina propria was found only on the apical portion of villi (24 h ligation time, F).
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Research objectives
Research objectives were the occluded superior anterior pancreaticoduodenal 
vein (SAPDV) and duodenal lesions (congestion) and the recovering effect 
(rapidly activated collaterals bypassing vascular occlusion, absent lesions), the 
therapy effect of stable gastric pentadecapeptide BPC 157 vs harmful effect 
of NO-agents [L-NAME (NO-system-blockade), L-arginine (NO-system over-
stimulation); L-NAME+L-arginine (NO-system immobilization)]. We recorded 
the vessel presentation (filled/appearance or emptied/disappearance) between 
the 5 arcade vessels arising from the SAPDV on the ventral duodenum side, 
the inferior anterior pancreaticoduodenal vein (IAPDV), superior mesenteric 
vein (SMV) as bypassing vascular pathway to document the duodenal lesions 
presentation. In duodenum, BPC 157 normalizes NO-levels and counteracts 
increased oxidative stress [malondialdehyde (MDA)]-levels.
Research methods
For research methods, we used rats with the occluded SAPDV and duodenal 
lesions (congestion) to reveal the recovering effect (rapidly activated collaterals 
bypassing vascular occlusion, absent lesions), at 5 min, 30 min and 24 h 
ligation time. Therapy effect of the stable gastric pentadecapeptide BPC 157 
was achieved with two regimens (10 μg, 10 ng/kg per 1 mL bath/rat or 10 
μg/kg instilled into the rat stomach), at 1 min ligation-time. Harmful effect of 
NO-agents [L-NAME (NO-system-blockade), L-arginine (NO-system over-
stimulation); L-NAME+L-arginine (NO-system immobilization)] goes with 
L-NAME 5 mg/kg per 1 mL bath/rat; L-arginine 100 mg/kg per 1 mL bath/rat, 
alone and/or together. Considering the point immediately before therapy (as 
100%), we scored the vessel presentation [recorded filled/appearance or 
emptied/disappearance (camera attached to a USB microscope)] between the 
5 arcade vessels arising from the SAPDV on the ventral duodenum side, the 
IAPDV, SMV as bypassing vascular pathway. Upon the duodenum opening 
and after sacrifice, we assessed the congested hemorrhagic areas as the 
sum of the largest lesion diameters. In the collected duodenal tissue samples, 
we assessed NO-levels (Griess reaction) and oxidative stress [by quantifying 
thiobarbituric acid-reactive species (TBARS) as MDA equivalents].
Research results
For research results, we attempted to alleviate major venous obstruction 
and duodenal lesions in rats with stable gastric pentadecapeptide BPC 157 
treatment and to investigate its relation to the NO system. In duodenal lesion 
development, the occlusion of the SAPDV appears as the key failure (before 
other vessel occlusions: i.e., left colic artery and vein ligation, and inferior caval 
vein ligation) that could never be spontaneously alleviated, even though well-
placed vessels or additional therapy with NO agents [NOS-over-activation 
(L-arginine) and/or NOS-blockade (L-NAME)]. On the other hand, BPC 157 
therapy resulted in promptly alleviated vascular presentation and then alleviated 
a perilous course of duodenal lesions in rats with SAPDV occlusions. We 
documented again “running” toward the bypassing vessel occlusion(s) and 
that BPC 157 after SAPDV occlusion quickly restores the blood supply to the 
ischemically injured area. BPC 157 rapidly activates collaterals much like a 
fundamental treatment that and counteracted the injurious course (ischemic 
colitis; the syndrome resulting from inferior caval vein infrarenal-ligation) and 
this effect involves the NO system and reduction of free radical formation.  
Research conclusions
The new phenomena that were found through experiments in this study of the 
duodenal lesions with an obstructed major vein (SAPDV) offered is the early 
positive outcome (“bypassing” effect) of BPC 157. The hypotheses that were 
confirmed through experiments in this study are related to the cytoprotective 
agents, to the effects originally noted in the stomach, which is the rapid 
endothelial protection. Using BPC 157 as a prototype cytoprotective agent, 
these mechanisms can prevent and resolve adjacent ischemic mucosal lesions 
providing activation of the collateral circulation. This activation is specific 
and can circumvent obstructions. That effect may be crucial for its persisting 
beneficial effect, even with continuous occlusions. The effect of BPC 157 in 
rats with SAPDV-ligation and previously, in rats with left colic artery and vein 
ligations may indicate that the action of BPC 157 overlaps in the duodenum and 
colon. BPC 157 plays an important role in with respect to the “bypassing” effect 
that maintains duodenum and colon mucosal integrity and interacts with the NO 
system [L-NAME and L-arginine exhibited parallel effects (lesion worsening), 
which mitigated each other] in SAPDV, left colic artery and vein circulation, 
and duodenal and colon lesions. Thus, these findings can be regarded as an 
implementation of the original cytoprotection concept in vascular occlusion 
therapy.
Research perspectives
For research perspectives, we attempted to alleviate major venous obstruction 
and duodenal lesions in rats with stable gastric pentadecapeptide BPC 157 
treatment and to investigate its relation to the NO system. In duodenal lesion 
development, the SAPDV occlusion appears as the key failure that could never 
be spontaneously alleviated, even though well-placed vessels or additional 
therapy with NO agents [NOS-overactivation (L-arginine) and/or NOS-blockade 
(L-NAME)]. Finally, BPC 157 therapy results in “bypassing” effect combined 
with mucosal integrity, or major vessel obstruction made harmless. These BPC 
157 effects can be an implementation of the original cytoprotection concept in 
vascular occlusion therapy. 
Figure 8  Nitric oxide levels and malondialdehyde levels in the duodenal tissue of superior anterior pancreaticoduodenal vein-ligated rats at 5 min, 30 
min and 24 h ligation. BPC 157 [10 μg/kg, 1 mL bath/rat (Bb), 1 mL instilled into the stomach (Big)] or an equal volume of a saline bath (CONb) or instillation in the 
stomach (CONig) (controls) was applied to superior anterior pancreaticoduodenal vein-ligated rats. aP < 0.05 vs saline; bP < 0.05 vs healthy duodenum. H: Healthy 
duodenum; Bb: BPC 157 10 μg/kg, 1 mL bath/rat; Big: BPC 157 10 μg/kg, 1 mL instilled into the stomach; CONb: 1 mL saline bath; CONig: 1 mL saline instillation in 
the stomach; NO: Nitric oxide; MDA: Malondialdehyde.
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